Fresenius’ goal is to ensure and expand its long-term position as a leading international provider of products and services in the health care industry. To this end, and to geographically expand our business, we plan to grow organically as well as through selective small to medium-sized acquisitions, complementing our existing portfolio. We focus on markets with strong growth rates.
Fresenius Medical Care is the worldwide leader in dialysis, with a strong market position in the United States. Future opportunities in dialysis will arise from further expansion in dialysis care and products worldwide, as well as the focused range in Care Coordination. In this area, Fresenius Medical Care offers additional services for the holistic care of patients and meets the increasing demand with this model.
Fresenius Kabi is the market leader in infusion therapy and/or clinical nutrition in Europe and in the key markets in Asia-Pacific (including China) and Latin America. In the United States, Fresenius Kabi is one of the leading players in the market for generic IV drugs. In addition, Fresenius Kabi is one of the most important providers of transfusion technology. Fresenius Kabi plans to roll out products from its existing portfolio to the growth markets and to launch existing products in the United States. Market share is to be expanded further through the launch of new products in the field of IV drugs, infusion therapy, clinical nutrition, and medical devices/transfusion technology.
With 86 hospitals, Fresenius Helios operates in nearly all of Germany. Building on this, Fresenius Helios is now in the position to develop new patient care models. To benefit from the trend towards outpatient treatment, Helios Germany has been expanding outpatient service offerings in a separate division since September 2018.
Helios Spain has attractive growth opportunities through the expansion and construction of hospitals, and potential for further consolidation in the highly fragmented private hospital market in Spain. Helios Health exploits upcoming opportunities for cross-border synergies in areas such as laboratory services and joint purchasing. The cross-border exchange of experience and knowledge is gradually creating the economic prerequisites for the further internationalization of our hospital business. Helios Spain announced the acquisition of Clínica Medellín in 2018. Fresenius Helios is thus entering the attractive private hospital market in Colombia.
Fresenius Vamed will further expand its position as a global specialist for projects and services for hospitals and other health care facilities. With the acquisition of Fresenius Helios’ German inpatient rehabilitation business, Fresenius Vamed developed itself into one of the leading providers of private rehabilitation services in Europe. Moreover, the cooperation with Fresenius Helios is being intensified, for example in technical services and procurement, where Fresenius Helios and Fresenius Vamed are now jointly purchasing certain products.